Ra Pharmaceuticals Inc Revenue Growth Rates (RARX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Ra Pharmaceuticals Inc   (RARX)
 

RARX's Revenue Growth by Quarter and Year

Ra Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RARX Revenue (in millions $) FY 2019 FY 2018 FY 2017 FY 2016
4th Quarter December 4.31
3rd Quarter September 3.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 7.31





RARX Revenue fourth quarter 2019 Y/Y Growth Comment
Ra Pharmaceuticals Inc achieved in the fourth quarter 2019, above Company average Revenue rise of 72.56% year on year, to $ 4.31 millions.

Looking into fourth quarter 2019 results within Major Pharmaceutical Preparations industry 54 other companies have achieved higher Revenue growth. While Ra Pharmaceuticals Inc ' s Revenue jump of 72.56% ranks overall at the positon no. 382 in the fourth quarter 2019.


RARX Revenue ( Y/Y Growth %) 2019
 2018 2017 2016
4th Quarter December 72.56 % - - -
3rd Quarter September - - - -
2nd Quarter June - - - 128.57 %
1st Quarter March - - - 121.18 %
FY   192.56 % - - -

Financial Statements
Ra Pharmaceuticals Inc 's fourth quarter 2019 Revenue $ 4.31 millions RARX's Income Statement
Ra Pharmaceuticals Inc 's fourth quarter 2018 Revenue $ 2.50 millions Quarterly RARX's Income Statement


RARX Revenue (Quarter on Quarter Growth %)

 2019
 2018 2017 2016
4th Quarter December 43.8 % - - -
3rd Quarter September - - - -
2nd Quarter June - - - 61.7 %
1st Quarter March - - - 129.27 %
FY (Year on Year)   192.56 % - - -


Back to RARX Growth rate Comparisons >> Back to RARX Growth rate Comparisons >>


Revenue fourth quarter 2019 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #55
Healthcare Sector #105
Overall #382

Revenue Y/Y Growth Statistics
High Average Low
129.22 % -10.9 % -100 %
(Dec 31 2019)  
Revenue fourth quarter 2019 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #55
Healthcare Sector #105
Overall #382
Revenue Y/Y Growth Statistics
High Average Low
129.22 % -10.9 % -100 %
(Dec 31 2019)  

Revenue by Quarter for the Fiscal Years 2016, 2017, 2018, 2019

Ra Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
43.8 % -28.1 % -100 %
(Dec 31 2019)  


RARX's IV. Quarter Q/Q Revenue Comment
Ra Pharmaceuticals Inc achieved in the IV. Quarter 2019 above company average sequential Revenue jump of 43.8%, to $ 4.31 millions, from $3.00 millions in the third quarter.
RARX is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 46 other companies have achieved higher Revenue quarter on quarter growth. While Ra Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 376.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #47
Healthcare Sector #97
Overall #376
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #47
Healthcare Sector #97
Overall #376
Revenue Q/Q Growth Statistics
High Average Low
43.8 % -28.1 % -100 %
(Dec 31 2019)  


RARX's IV. Quarter Q/Q Revenue Comment
Ra Pharmaceuticals Inc achieved in the IV. Quarter 2019 above company average sequential Revenue jump of 43.8%, to $ 4.31 millions, from $3.00 millions in the third quarter.
RARX is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 46 other companies have achieved higher Revenue quarter on quarter growth. While Ra Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 376.


Ra Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2019)		 12 Months Ending
(Sep 30 2019)		 12 Months Ending
(Jun 30 2019)		 12 Months Ending
(Mar 31 2019)		 12 Months Ending
(Dec 31 2018)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #


Cumulative Revenue growth Comment
In the Dec 31 2019 period, Ra Pharmaceuticals Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Ra Pharmaceuticals Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Dec 31 2019 period, Ra Pharmaceuticals Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Ra Pharmaceuticals Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
RARX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Dec 31 2019 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2019
Progyny Inc 123.12%$ 123.120 millions
Vaxart Inc 121.62%$ 121.619 millions
Ultragenyx Pharmaceutical Inc 118.89%$ 118.886 millions
Chemocentryx Inc.115.32%$ 115.324 millions
Spero Therapeutics Inc 114.54%$ 114.539 millions
Lumos Pharma Inc 114.36%$ 114.356 millions
Invo Fertility Inc 111.86%$ 111.863 millions
Boston Scientific Corporation110.61%$ 110.613 millions
Infinity Pharmaceuticals Inc 110.27%$ 110.274 millions
Harpoon Therapeutics Inc 110.16%$ 110.160 millions
Ontrak Inc 109.07%$ 109.068 millions
Biocardia Inc 107.77%$ 107.767 millions
Biocept Inc 107.53%$ 107.526 millions
Exact Sciences Corporation106.72%$ 106.723 millions
Sangamo Therapeutics Inc 104.39%$ 104.386 millions
Antares Pharma Inc 101.05%$ 101.047 millions
Editas Medicine Inc 100.75%$ 100.752 millions
Dynavax Technologies Corporation98.76%$ 98.759 millions
Nephros Inc 96.09%$ 96.092 millions
Misonix Inc 93.80%$ 93.800 millions
Guardant Health Inc 91.33%$ 91.333 millions
Portola Pharmaceuticals inc 91.19%$ 91.188 millions
Accelerate Diagnostics Inc 90.45%$ 90.450 millions
Precision Optics Corporation Inc 89.25%$ 89.245 millions
Sorrento Therapeutics Inc 88.11%$ 88.108 millions
Elite Pharmaceuticals Inc 87.65%$ 87.646 millions
Theravance Biopharma inc 87.45%$ 87.450 millions
Neurocrine Biosciences Inc 85.57%$ 85.570 millions
Amarin Corp Plcuk85.28%$ 85.282 millions
Miragen Therapeutics Inc 84.87%$ 84.874 millions


About Ra Pharmaceuticals Inc Revenue Growth Rates (RARX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.